Canadian application, no grantCanada
Human cd45+ and/or fibroblast + mesenchymal stem cells
CA 2328524 A1 · Owner: Osiris Therapeutics, Inc. · Inventors: Mcneil, Renee Marie; Moorman, Mark Aaron; Craig, Stewart
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Human mesenchymal stem cells having the phenotype SH3+ CD45+ can be isolated. , These precursor mesenchymal item cells are useful for treatment of patients in need of mesenchymal stem cells.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 28, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 28, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 28, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledMay 28, 1999
GrantedNo grant recorded
Term endedMay 28, 2019
Patent numberCA 2328524 A1
Classification (IPC)C12N5/07 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.